Biomet Oxford Knee PMA Inspection In UK Results In FDA Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Biomet says it will consider alternative production sites for its Stanmore hip, Copeland shoulder and Oxford knee implantable devices if the company and FDA are unable to resolve sterilization and validation issues in a timely fashion at a UK facility identified by the agency in a Feb. 19 warning letter